Non-cardiogenic pulmonary edema is an increased-permeability pulmonary edema resulting from injury to the alveolar epithelial–endothelial barrier, leading to protein-rich fluid accumulation in the alveolar space, distinct from hydrostatic (cardiogenic) edema. [1-2] The most severe and common clinical manifestation is ARDS, but NCPE also encompasses drug-induced, neurogenic, high-altitude, transfusion-related (TRALI), immersion, and re-expansion etiologies. [3-6]
1. History
- Onset and timeline: Acute dyspnea developing within hours to days of a known insult (pneumonia, sepsis, aspiration, trauma, drug exposure, altitude change, transfusion, neurologic event) [1-3]
- Symptom characterization: Progressive dyspnea, tachypnea, cough, frothy sputum (may be pink-tinged); hypoxemia refractory to supplemental oxygen [2][7]
- Key HPI questions:
- Recent infection, surgery, or trauma?
- Aspiration risk (decreased LOC, vomiting, intoxication)?
- Blood product transfusion within the past 6 hours (TRALI)? [8]
- Medication/drug use — opioids, salicylates, chemotherapy (cytarabine, gemcitabine, IL-2, ATRA)? [9-11]
- Recent altitude exposure >2500 m? [4]
- Acute neurologic event (SAH, TBI, seizure)? [5]
- Immersion/diving history? [12]
- Important negatives: Absence of orthopnea, PND, weight gain, or peripheral edema argues against cardiogenic etiology [2]
2. Alarm Features
- Refractory hypoxemia (SpO₂ <88% despite high-flow O₂)
- Respiratory rate >30 with accessory muscle use or inability to speak in full sentences
- Altered mental status — may indicate impending respiratory failure or neurogenic etiology [5][13]
- Hemodynamic instability — hypotension, tachycardia, signs of septic shock
- Rapid progression from mild dyspnea to respiratory failure within hours
- PaO₂/FiO₂ ≤100 mmHg = severe ARDS with mortality 45–60% [7][14]
- Multi-organ dysfunction — ARDS frequently progresses to MODS, the primary cause of death [15]
3. Medications
Causative agents (drug-induced NCPE)
- Opioids (heroin, morphine, methadone) — most common drug-induced cause; mechanism involves increased capillary permeability [9][11]
- Salicylates — NCPE in 35% of intoxicated patients >30 years old; risk factors include chronic ingestion, smoking, metabolic acidosis, neurologic symptoms [16-17]
- Chemotherapy: cytarabine, gemcitabine, IL-2, all-trans retinoic acid (differentiation syndrome) [10]
- Naloxone — negative-pressure pulmonary edema from laryngospasm after rapid opioid reversal (incidence ~1.1%) [18]
- Hydrochlorothiazide, tocolytics, NSAIDs (rare) [9][19]
Treatments (see Treatment Plan below)
- No specific pharmacotherapy for NCPE/ARDS has proven mortality benefit beyond corticosteroids (conditional recommendation for moderate-to-severe ARDS) [20-21]
- Treat the underlying cause (antibiotics for sepsis/pneumonia, hemodialysis for salicylate toxicity, descent for HAPE)
Contraindicated/caution
- Avoid routine diuretics unless true volume overload is present (NCPE is a permeability problem, not a hydrostatic one) [2]
- Avoid beta-blockers in the acute setting [22]
- Caution with aggressive IV fluid resuscitation — target net neutral-to-negative fluid balance once shock resolves [21][23]
4. Diet
- NPO if intubation is anticipated or aspiration risk is high
- Fluid restriction — conservative fluid strategy is recommended once hemodynamically stable; aggressive diuresis may be needed to achieve net negative balance [23]
- Enteral nutrition should be initiated early (within 24–48 hours) in ICU patients per critical care guidelines, preferring trophic feeds initially
- Long-term: No specific dietary modifications for NCPE itself; address underlying condition (e.g., alcohol cessation if alcohol-related ARDS risk)
5. Review of Systems
- Pulmonary: Dyspnea, cough, sputum production, hemoptysis
- Infectious: Fever, chills, rigors, productive cough (pneumonia/sepsis)
- Neurologic: Headache, seizure, focal deficits (neurogenic pulmonary edema) [5]
- GI: Nausea, vomiting, abdominal pain (aspiration risk, pancreatitis)
- Hematologic: Recent transfusions (TRALI) [8]
- Toxicologic: Drug ingestion, opioid use, salicylate use [11][16]
- Cardiac: Chest pain, palpitations (to exclude cardiogenic causes)
- Musculoskeletal: Trauma history
6. Collateral History and Family History
- Collateral: Witnesses to aspiration event, drug ingestion, or trauma; EMS report on scene findings; medication list from pharmacy
- Social context: IV drug use (opioid-induced NCPE), alcohol use disorder (increases ARDS risk), smoking history [3]
- Family history: Generally not contributory, though rare genetic variants (e.g., haptoglobin Hp-2) may modestly increase ARDS susceptibility in sepsis [3]
- HAPE: Prior episodes of high-altitude pulmonary edema confer 60% recurrence risk [4]
7. Risk Factors
- Pneumonia — most common precipitant of ARDS [3][24]
- Non-pulmonary sepsis [1][3]
- Aspiration of gastric contents [3]
- Major trauma with shock and massive transfusion [3]
- Pancreatitis [3]
- Burns and inhalation injury [1]
- Alcohol use disorder and cigarette smoking — increase likelihood of developing ARDS from any inciting condition [3]
- Massive blood product transfusion (TRALI/TACO) [8]
- Drug overdose (opioids, salicylates) [9][11]
- Rapid altitude ascent >2500–3000 m [4]
- Acute brain injury (SAH, TBI, status epilepticus) — neurogenic pulmonary edema in 20–30% [13]
8. Differential Diagnosis
- Cardiogenic pulmonary edema — most important to distinguish; look for S3 gallop, elevated BNP, cardiomegaly, response to diuretics [2][25]
- Pulmonary embolism — acute dyspnea, hypoxemia; D-dimer, CTA chest [26]
- Bilateral pneumonia without ARDS — may have similar imaging but without the severity of hypoxemia
- Diffuse alveolar hemorrhage — hemoptysis, dropping hemoglobin, BAL with progressively bloody returns
- Acute eosinophilic pneumonia — peripheral eosinophilia, BAL eosinophils >25%
- Interstitial lung disease (acute exacerbation) — pre-existing fibrotic changes on CT [23]
- Lymphangitic carcinomatosis — subacute onset, known malignancy
- TACO vs. TRALI — both post-transfusion; TACO has elevated BNP and signs of volume overload; TRALI is non-cardiogenic and occurs within 6 hours [8]
The following algorithm from Ware and Matthay (NEJM) outlines a stepwise approach to differentiating cardiogenic from non-cardiogenic pulmonary edema:
9. Past Medical History
- Prior ARDS episodes (recurrence risk exists)
- Chronic lung disease (COPD, ILD) — lower pulmonary reserve
- Heart failure or valvular disease — may have mixed cardiogenic/non-cardiogenic edema (~10% of cases) [2]
- Immunosuppression — increased infection risk as precipitant
- Chronic kidney disease — complicates fluid management
- Prior high-altitude pulmonary edema — high recurrence risk [4]
- Substance use disorder — opioid, alcohol
10. Physical Exam
- Vitals: Tachypnea (often >30/min), tachycardia, hypoxemia (SpO₂ often <90% on room air), may be hypotensive (sepsis) or hypertensive (neurogenic)
- Pulmonary: Bilateral crackles/rales, decreased breath sounds, increased work of breathing, accessory muscle use
- Cardiac: Absence of S3 gallop, JVD, and peripheral edema helps distinguish from cardiogenic edema (S3 specificity 90–97% for cardiogenic) [2]
- Neurologic: Assess GCS — altered mental status may indicate neurogenic etiology or impending respiratory failure [5]
- Skin: Cyanosis, mottling (sepsis), track marks (IV drug use)
- Abdomen: Tenderness (pancreatitis as precipitant)
11. Lab Studies
- ABG/VBG: Assess PaO₂/FiO₂ ratio for ARDS severity classification; expect hypoxemia with increased A-a gradient [1][7]
- BNP/NT-proBNP: BNP <100 pg/mL makes cardiogenic edema unlikely; however, discriminatory ability is moderate (AUC 0.67–0.87) [2][25]
- Lactate: Elevated in sepsis, shock
- CBC: Leukocytosis (infection), anemia (hemorrhage)
- CMP: Renal function (fluid management), hepatic function
- Procalcitonin: Supports infectious etiology [27]
- Blood cultures: If sepsis suspected
- Salicylate level: In any unexplained NCPE with altered mental status or anion gap acidosis [16][28]
- Toxicology screen: Opioids, other ingestions [27]
- Troponin: Rule out ACS as contributor
- Edema fluid-to-plasma protein ratio: ≥0.65 supports NCPE (sensitivity and specificity ~81%), though not routinely performed [29]
12. Imaging
First-line: Chest X-ray
- NCPE: Bilateral diffuse alveolar opacities, normal heart size, normal vascular pedicle width, peripheral/patchy distribution, air bronchograms; absence of Kerley B lines and cephalization [2][6]
- Cardiogenic: Enlarged cardiac silhouette, cephalization, Kerley B lines, peribronchial cuffing, pleural effusions [30]
Point-of-care ultrasound (POCUS)
- Bilateral B-lines confirm pulmonary edema but do not differentiate cardiogenic from non-cardiogenic [23][31]
- Combined cardiac + lung POCUS improves differentiation: normal LV function, small IVC, and absence of pleural effusion favor NCPE; decreased LV function, dilated IVC >23 mm, and left pleural effusion favor cardiogenic (AUC 0.79) [32]
CT Chest
- Quantifies lung edema and recruitability; identifies mimics (PE, masses, ILD) [23]
- ARDS pattern: dependent consolidation with anterior ground-glass opacities, heterogeneous distribution [33]
- Specific patterns: neurogenic PE → bilateral apical-predominant consolidation; HAPE → central patchy consolidation [6]
When imaging is unnecessary: Imaging is always indicated when NCPE is suspected
The following figure demonstrates the radiographic and CT progression of ARDS from the acute exudative phase to the fibrosing-alveolitis phase:
13. Special Tests
- Berlin Definition criteria for ARDS classification (mild/moderate/severe based on PaO₂/FiO₂) [1]
- Lung Injury Prediction Score (LIPS) — identifies patients at risk for developing ARDS
- POCUS B-line quantification: ≥3 B-lines in ≥2 zones = abnormal; semi-quantitative scoring correlates with extravascular lung water [34-35]
- Pulmonary artery catheterization: PCWP ≤18 mmHg confirms non-cardiogenic etiology; reserved for diagnostic uncertainty or mixed presentations [2]
- Echocardiography: Assess LV/RV function, valvular disease; required to exclude hydrostatic edema if no clear ARDS risk factor is present [1]
- Bronchoscopy with BAL: Consider if diffuse alveolar hemorrhage, eosinophilic pneumonia, or opportunistic infection is suspected
14. ECG
- Indications: All patients with acute pulmonary edema to rule out ischemia/arrhythmia as cardiogenic contributor [2][27]
- Expected findings in NCPE: Sinus tachycardia; no ischemic changes
- Concerning patterns: ST changes (ACS → cardiogenic component), RV strain pattern (S1Q3T3, right axis deviation → PE), new arrhythmia
- Neurogenic PE: May see QT prolongation, ST-T wave changes, or arrhythmias related to catecholamine surge [36]
15. Assessment
Severity stratification (Berlin Definition): [1]
- Mild: PaO₂/FiO₂ 200–300 mmHg (mortality ~27%)
- Moderate: PaO₂/FiO₂ 100–200 mmHg (mortality ~32%)
- Severe: PaO₂/FiO₂ ≤100 mmHg (mortality ~45%)
NCPE/ARDS is present in ~10% of all ICU admissions and ~24% of mechanically ventilated patients. [24][37] Overall mortality remains 30–40% despite advances in supportive care. [24] Approximately 10% of patients have mixed cardiogenic and non-cardiogenic edema, complicating diagnosis. [2] Complications include ventilator-induced lung injury, barotrauma, nosocomial infections, multi-organ dysfunction, and ICU-acquired weakness. [14-15]
16. Treatment Plan
Initial stabilization
- Airway/breathing: Supplemental O₂ targeting SpO₂ 88–92%; escalate to high-flow nasal cannula or NIPPV for mild ARDS [1][38]
- Intubation: If refractory hypoxemia, respiratory fatigue, or inability to protect airway
Lung-protective ventilation (strong recommendation): [20-21]
- Tidal volume 4–8 mL/kg predicted body weight
- Plateau pressure ≤30 cm H₂O
- Driving pressure <15 cm H₂O
- PEEP ≥5 cm H₂O; higher PEEP for moderate-to-severe ARDS [20]
Adjunctive therapies
- Prone positioning: ≥12–17 hours/day for moderate-to-severe ARDS (PaO₂/FiO₂ <150) — strong recommendation [20][23]
- Corticosteroids: Suggested for moderate-to-severe ARDS within 14 days of onset (dexamethasone 20 mg IV daily × 5 days, then 10 mg × 5 days is a common regimen); administration past 14 days may worsen outcomes [20-21]
- Neuromuscular blockade: Consider in early severe ARDS with refractory hypoxemia or ventilator dyssynchrony; goal duration <48 hours [20][23]
- Conservative fluid strategy: Target net neutral-to-negative fluid balance once off vasopressors [23]
- VV-ECMO: For severe refractory ARDS (PaO₂/FiO₂ <80 despite optimal ventilation) at an ECMO-capable center [14][20]
Treat the underlying cause
- Antibiotics for pneumonia/sepsis
- Urinary alkalinization + hemodialysis for salicylate toxicity [28][39]
- Naloxone for opioid-induced NCPE (use cautiously — can precipitate negative-pressure PE) [18]
- Descent + supplemental O₂ for HAPE; nifedipine 30 mg SR if descent delayed [4]
- Discontinue offending chemotherapy agent + IV corticosteroids for drug-induced NCPE [10]
Prophylaxis: Stress ulcer prophylaxis + DVT prophylaxis with LMWH [23]
17. Disposition
- ICU admission: All patients with moderate-to-severe ARDS, those requiring mechanical ventilation, hemodynamically unstable patients, or those needing vasoactive medications [27]
- Monitored bed/step-down: Mild ARDS on HFNC or NIPPV with stable hemodynamics
- Observation: Rarely appropriate — most NCPE requires at minimum monitored admission
- Discharge: Not appropriate in the acute phase; discharge only after resolution of hypoxemia, ability to ambulate without desaturation, and treatment of underlying cause [27]
- Transfer: Consider transfer to ECMO-capable center for severe refractory ARDS [14][20]
- Specialist consultation triggers: Pulmonary/critical care for all ARDS; toxicology for drug-induced NCPE; neurosurgery for neurogenic PE; cardiothoracic surgery if ECMO considered
18. Follow Up / Return Precautions
Post-ICU follow-up is critical — ARDS survivors experience significant Post-Intensive Care Syndrome (PICS): [1][40-41]
- Physical: Persistent muscle weakness, reduced 6-minute walk distance (~66% predicted at 12 months), fatigue; 44% of previously employed survivors are jobless at 1 year [1][42]
- Cognitive: Impairments in memory, attention, executive function, and processing speed in up to 30% at 1 year [43-44]
- Psychiatric: PTSD (up to 25%), depression and anxiety (up to 50%) [1][42]
- Pulmonary: Fibrotic changes on CT in 43–70% of survivors; mild restrictive deficits and reduced DLCO common [43][45]
The following figure from Herridge et al. demonstrates the trajectory of functional recovery over 5 years after ARDS, showing persistent physical limitation:
Follow-up timing
- ICU recovery clinic at 1–3 months post-discharge, then at 6 and 12 months [41]
- PFTs at 3–6 months
- Screen for depression, anxiety, PTSD at each visit
- Pulmonary rehabilitation referral
Return precautions (for patients discharged after milder episodes):
- Return immediately for worsening dyspnea, new fever, SpO₂ <92%, chest pain, confusion, or inability to perform daily activities
- Expected recovery: Rapid improvement in the first 6–12 months, but physical function may plateau below baseline for up to 5 years [1][46]
Late mortality: 11% at 1 year, 20–34% at 5 years; hospital readmission in up to 40% of survivors [1]
References
1. Acute Respiratory Distress Syndrome in Adults: Diagnosis, Outcomes, Long-Term Sequelae, and Management. — Gorman EA, O'Kane CM, McAuley DF. Lancet. 2022.
2. Acute Pulmonary Edema. — Ware LB, Matthay MA. The New England Journal of Medicine. 2005.
3. Acute Respiratory Distress Syndrome: Causes, Pathophysiology, and Phenotypes. — Bos LDJ, Ware LB. Lancet. 2022.
4. Acute High-Altitude Illnesses. — Bärtsch P, Swenson ER. The New England Journal of Medicine. 2013.
5. Neurogenic Pulmonary Edema. — Busl KM, Bleck TP. Critical Care Medicine. 2015.
6. Clinical and Radiologic Features of Pulmonary Edema. — Gluecker T, Capasso P, Schnyder P, et al. Radiographics : A Review Publication of the Radiological Society of North America, Inc. 1999.
7. Acute Respiratory Distress Syndrome: Diagnosis and Management. — Saguil A, Fargo MV. American Family Physician. 2020.
8. Evaluation of pulmonary abnormalities in recipients of hematopoietic cell transplants and cellular therapies. — Thomas L, Boatman J. Transplant Infectious Disease : An Official Journal of the Transplantation Society. 2023.
9. Drug-Induced Respiratory Disorders: Incidence, Prevention and Management. — Ben-Noun L. Drug Safety. 2000.
10. Noncardiogenic Pulmonary Edema: An Unusual and Serious Complication of Anticancer Therapy. — Briasoulis E, Pavlidis N. The Oncologist. 2001.
11. The Effects of Opioids on the Lung. — Radke JB, Owen KP, Sutter ME, Ford JB, Albertson TE. Clinical Reviews in Allergy & Immunology. 2014.
12. An Update on Environment-Induced Pulmonary Edema - "When the Lungs Leak Under Water and in Thin Air". — Tetzlaff K, Swenson ER, Bärtsch P. Frontiers in Physiology. 2022.
13. Pathophysiology and Management of Neurogenic Pulmonary Edema in Patients With Acute Severe Brain Injury. — Maslonka MA, Sheehan KN, Datar SV, Vachharajani V, Namen A. Southern Medical Journal. 2022.
14. Extracorporeal Support for Acute Respiratory Distress Syndrome in Adults. — Munshi L, Brodie D, Fan E. NEJM Evidence. 2022.
15. Acute Respiratory Distress Syndrome: Pathophysiological Insights, Subphenotypes, and Clinical Implications-a Comprehensive Review. — Ziaka M, Exadaktylos A. Journal of Clinical Medicine. 2025.
16. Salicylate-Induced Pulmonary Edema. — Walters JS, Woodring JH, Stelling CB, Rosenbaum HD. Radiology. 1983.
17. Salicylate-Induced Pulmonary Edema. Clinical Features and Prognosis. — Heffner JE, Sahn SA. Annals of Internal Medicine. 1981.
18. Opioid-Associated Out-of-Hospital Cardiac Arrest: Distinctive Clinical Features and Implications for Health Care and Public Responses: A Scientific Statement From the American Heart Association. — Dezfulian C, Orkin AM, Maron BA, et al. Circulation. 2021.
19. Nonsteroidal Anti-Inflammatory Drug-Induced Acute Respiratory Distress Syndrome. — Özbek AE, Divrikoğlu YS, Yılmaz S, Aytaş NÜ, Çelik E. The American Journal of Emergency Medicine. 2018.
20. An Update on Management of Adult Patients With Acute Respiratory Distress Syndrome: An Official American Thoracic Society Clinical Practice Guideline. — Qadir N, Sahetya S, Munshi L, et al. American Journal of Respiratory and Critical Care Medicine. 2024.
21. Emergency Medicine Updates: Acute Respiratory Distress Syndrome. — Long B, Lentz S, Gottlieb M. The American Journal of Emergency Medicine. 2025.
22. Emergency Medicine Updates: Sympathetic Crashing Acute Pulmonary Edema. — Long B, Brady WJ, Gottlieb M. The American Journal of Emergency Medicine. 2025.
23. Acute Respiratory Distress Syndrome. — Meyer NJ, Gattinoni L, Calfee CS. Lancet. 2021.
24. Acute Respiratory Distress Syndrome. — Matthay MA, Zemans RL, Zimmerman GA, et al. Nature Reviews. Disease Primers. 2019.
25. A Systematic Review of Diagnostic Methods to Differentiate Acute Lung Injury/Acute Respiratory Distress Syndrome From Cardiogenic Pulmonary Edema. — Komiya K, Akaba T, Kozaki Y, Kadota JI, Rubin BK. Critical Care. 2017.
26. Predictive Value of Clinical and Laboratory Parameters in Differentiating Hypertensive Pulmonary Edema and Acute Pulmonary Embolism. — Kavvasoglu B, Kavvasoglu GH. European Review for Medical and Pharmacological Sciences. 2023.
27. Acute Care of Patients With Moderate Respiratory Distress: Recommendations From an American College of Emergency Physicians Expert Panel. — Baugh CW, Neuenschwander JF, Lenox J, et al. The Western Journal of Emergency Medicine. 2025.
28. Chronic Salicylism Resulting in Noncardiogenic Pulmonary Edema Requiring Hemodialysis. — Cohen DL, Post J, Ferroggiaro AA, Perrone J, Foster MH. American Journal of Kidney Diseases : The Official Journal of the National Kidney Foundation. 2000.
29. Determining the Aetiology of Pulmonary Oedema by the Oedema Fluid-to-Plasma Protein Ratio. — Ware LB, Fremont RD, Bastarache JA, Calfee CS, Matthay MA. The European Respiratory Journal. 2010.
30. Does This Patient Have Volume Overload?. — Drum B, La Course B, Kelly M, et al. The Journal of the American Medical Association. 2026.
31. The Practice and Implications of Finding Fluid During Point-of-Care Ultrasonography: A Review. — Liu RB, Donroe JH, McNamara RL, Forman HP, Moore CL. JAMA Internal Medicine. 2017.
32. Critical Care Ultrasonography Differentiates ARDS, Pulmonary Edema, and Other Causes in the Early Course of Acute Hypoxemic Respiratory Failure. — Sekiguchi H, Schenck LA, Horie R, et al. Chest. 2015.
33. The Acute Respiratory Distress Syndrome. — Ware LB, Matthay MA. The New England Journal of Medicine. 2000.
34. Ultrasound of Extravascular Lung Water: A New Standard for Pulmonary Congestion. — Picano E, Pellikka PA. European Heart Journal. 2016.
35. Cardiopulmonary Point-of-Care Ultrasonography for Hospitalist Management of Undifferentiated Dyspnea. — Maganti K, Chen C, Jamthikar AD, et al. JAMA Network Open. 2025.
36. Pathogenetic Mechanisms of Neurogenic Pulmonary Edema. — Šedý J, Kuneš J, Zicha J. Journal of Neurotrauma. 2015.
37. Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment. — Fan E, Brodie D, Slutsky AS. The Journal of the American Medical Association. 2018.
38. Severe Hypoxemia: Which Strategy to Choose. — Chiumello D, Brioni M. Critical Care. 2016.
39. Current Management of Salicylate-Induced Pulmonary Edema. — Glisson JK, Vesa TS, Bowling MR. Southern Medical Journal. 2011.
40. Improving Management of ARDS: Uniting Acute Management and Long-Term Recovery. — Latronico N, Eikermann M, Ely EW, Needham DM. Critical Care. 2024.
41. Updates on Post-Intensive Care Syndrome After Acute Respiratory Distress Syndrome: Epidemiology, Core Outcomes, Interventions, and Long-Term Follow-Up. — Hiser SL, Fatima A, Dinglas VD, Needham DM. Clinics in Chest Medicine. 2024.
42. Physical and Psychological Impairment in Survivors of Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis. — Fazzini B, Battaglini D, Carenzo L, et al. British Journal of Anaesthesia. 2022.
43. Outcomes after Critical Illness. — Herridge MS, Azoulay É. The New England Journal of Medicine. 2023.
44. Long-Term Cognitive Impairment After Acute Respiratory Distress Syndrome: A Review of Clinical Impact and Pathophysiological Mechanisms. — Sasannejad C, Ely EW, Lahiri S. Critical Care. 2019.
45. Post-Intensive Care Syndrome and Pulmonary Fibrosis in Patients Surviving ARDS-pneumonia of COVID-19 and Non-Covid-19 Etiologies. — Sturgill JL, Mayer KP, Kalema AG, et al. Scientific Reports. 2023.
46. Functional Disability 5 Years after Acute Respiratory Distress Syndrome. — Herridge MS, Tansey CM, Matté A, et al. The New England Journal of Medicine. 2011.